Mounjaro vs Zepbound: Same Drug, Different Indication
Why Eli Lilly markets tirzepatide twice and what that means for cost and coverage.
Key takeaways
Mounjaro and Zepbound are the same molecule (tirzepatide) made by Eli Lilly, but FDA-approved for different indications: Mounjaro for type 2 diabetes, Zepbound for chronic weight management and obstructive sleep apnea in adults with obesity.
Both products use identical active ingredients, dose strengths (2.5 mg through 15 mg), and weekly subcutaneous injection schedules — the clinical pharmacology is the same drug.
Insurance coverage usually differs by brand: Mounjaro is more often covered for diabetes, while Zepbound coverage for obesity depends on whether the plan includes anti-obesity medication benefits.
List prices have historically been similar (around $1,000–$1,300 per month before discounts), but Lilly's LillyDirect self-pay vials for Zepbound have made cash pricing meaningfully lower for some doses.
Switching brands does not change the medication — it changes the label, coverage, and how the prescription is documented; only a licensed prescriber can decide which is appropriate.
Why one molecule has two brand names
Mounjaro and Zepbound are the same medication: tirzepatide, a once-weekly injectable made by Eli Lilly. Both contain the exact same active ingredient in the same dose strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg), and both are delivered through the same single-dose pen format. The pharmacology, mechanism of action, and clinical effects on weight and blood sugar are identical because the drug inside is identical.
The reason there are two brand names comes down to how the U.S. Food and Drug Administration (FDA) regulates approved uses. The FDA approves drugs for specific conditions, called indications. Mounjaro was approved first, in May 2022, for adults with type 2 diabetes. Zepbound was approved later, in November 2023, for chronic weight management in adults with obesity, and then expanded in December 2024 to also cover moderate-to-severe obstructive sleep apnea in adults with obesity.
Manufacturers often launch one molecule under two brand names when the underlying indications have different payers, prescribers, and pricing realities. Diabetes drugs are usually paid for by insurance with relatively predictable formularies. Anti-obesity medications historically have spottier coverage, and many patients pay cash. Splitting the brands lets Lilly tailor pricing, packaging, and patient-support programs to each population while keeping the molecule the same.
Mounjaro's FDA label covers adults with type 2 diabetes as an adjunct to diet and exercise to improve glycemic control. It is not approved for weight loss specifically, even though weight loss is a documented and common effect in trials. Mounjaro is also not approved for type 1 diabetes, and the label notes it has not been studied in patients with a history of pancreatitis.
Zepbound's FDA label is for chronic weight management in adults with obesity (BMI 30 or greater) or overweight (BMI 27 or greater) with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. In late 2024, the FDA expanded Zepbound to also treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, making it the first medication approved for that combined indication.
These distinctions are not just paperwork. Prescribers, pharmacy benefit managers, and prior-authorization systems all key off the FDA-approved indication. If you have type 2 diabetes, your insurance is more likely to cover the diabetes-indicated brand. If you have obesity without diabetes, the obesity-indicated brand is usually the only one your insurer will even consider — and many plans still exclude anti-obesity medications entirely.
What the trials actually showed
Mounjaro's approval was based on the SURPASS clinical program in adults with type 2 diabetes. Across SURPASS-1 through SURPASS-5, tirzepatide produced large reductions in A1C (a measure of average blood sugar). In SURPASS-2, the 15 mg dose lowered A1C by about 2.3 percentage points versus 1.9 with semaglutide 1 mg, and participants on the highest tirzepatide dose lost an average of around 12 kg over 40 weeks.
Zepbound's approval was based on the SURMOUNT program. In SURMOUNT-1, adults with obesity but without diabetes who took the 15 mg dose for 72 weeks lost an average of about 20.9% of body weight, compared with around 3.1% in the placebo group. SURMOUNT-2, in adults with both obesity and type 2 diabetes, showed weight loss of about 14.7% at the highest dose. SURMOUNT-OSA later supported the sleep apnea indication, showing meaningful reductions in apnea-hypopnea index.
Because the active drug is identical, the trial outcomes apply biologically to anyone taking tirzepatide — but the labeled indication you are treated for matters for legal prescribing, insurance billing, and the safety monitoring your clinician does. As always, real-world results vary, and trial percentages are averages that include people who lost much more and much less.
Price and self-pay differences
List prices for Mounjaro and Zepbound have historically been close — roughly $1,000 to $1,300 per month before insurance or manufacturer discounts, depending on the dose. The list price is rarely what patients actually pay, though. Net cost depends on insurance coverage, manufacturer savings cards, and any cash-pay programs.
In 2024, Lilly launched LillyDirect, a direct-to-patient channel that sells Zepbound in single-dose vials at lower self-pay prices than the autoinjector pens — historically around $349 for 2.5 mg and $499 for 5 mg per month for eligible cash-paying patients, with higher tiers added later. There is no equivalent cash-pay vial program for Mounjaro because Mounjaro is intended to be billed through diabetes insurance benefits.
Manufacturer savings cards also differ. The Mounjaro savings card has typically reduced commercially insured patients' out-of-pocket cost to as low as $25 per month if the drug is on their formulary, with higher caps for patients whose insurance does not cover it. Zepbound's savings card structure has changed over time and is generally less generous for patients without anti-obesity coverage. Always check the manufacturer's current terms — these programs are revised frequently.
Insurance coverage: where the brands really diverge
From a pharmacology standpoint, choosing between and is a coin flip — same drug. From an insurance standpoint, it is rarely a choice at all. Insurance plans cover indications, not molecules. If you have type 2 diabetes, your plan's pharmacy formulary will typically list Mounjaro as a covered diabetes medication, often with a prior authorization requirement confirming your diagnosis and prior therapies.
If you have obesity without diabetes, your plan may or may not cover Zepbound. Many employer plans and most Medicare Part D plans historically have excluded anti-obesity medications entirely, although coverage is expanding slowly, particularly after Zepbound's sleep apnea indication. Medicaid coverage of anti-obesity drugs varies state by state. Even when Zepbound is covered, prior authorization usually requires documented BMI, weight-related comorbidities, and sometimes a trial of lifestyle intervention.
This is the single biggest practical reason Lilly maintains two brands. A diabetes drug routed through diabetes coverage is a fundamentally different reimbursement product than an obesity drug routed through anti-obesity coverage, even when the molecule, dose, and pen are identical.
Side effects and safety: identical for both
Because Mounjaro and Zepbound are the same drug, their side effect profiles are the same. The most common adverse effects in trials were gastrointestinal: nausea, diarrhea, vomiting, constipation, abdominal pain, and decreased appetite. These tend to be worst during dose escalation and improve over weeks for most patients, though some people stop the medication because of GI intolerance.
Both labels carry a boxed warning for the risk of thyroid C-cell tumors based on rodent studies. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Both labels warn about pancreatitis, gallbladder disease, hypoglycemia (particularly when combined with insulin or sulfonylureas), acute kidney injury from dehydration, diabetic retinopathy complications in patients with diabetes, and severe allergic reactions.
Additional warnings include a possible risk of pulmonary aspiration during anesthesia because tirzepatide slows stomach emptying. Patients are commonly advised to discuss timing of doses with surgical and anesthesia teams. Your prescriber will determine whether tirzepatide is appropriate for you and what monitoring is needed.
Can you switch between Mounjaro and Zepbound?
Clinically, switching between Mounjaro and Zepbound at the same dose is essentially seamless because the drug is identical. The question is rarely about pharmacology — it is about coverage, supply, and documentation. People often want to switch because their insurance situation changes, because one product is in shortage, or because cash-pay pricing for one is more attractive than the other.
Switching is not a do-it-yourself decision, though. The prescription must be written and billed under the brand whose label matches your diagnosis. A patient with type 2 diabetes getting Mounjaro should not simply ask for a Zepbound script unless they also meet the obesity indication and the prescriber agrees the obesity label is appropriate. A patient on Zepbound for obesity who develops type 2 diabetes may transition to Mounjaro for proper indication-based billing.
Compounded versions add another layer of complexity. is not the same regulatory product as Mounjaro or Zepbound. It is prepared by individual compounding pharmacies and is not FDA-approved as a finished product. The FDA removed tirzepatide from its drug shortage list in late 2024, which limited most large-scale compounding. Anyone considering switching to or from a compounded product should review current FDA guidance and discuss with their clinician.
How to think about the choice with your prescriber
When you sit down with a clinician, the practical question is rarely "Mounjaro or Zepbound" in a vacuum. It is: what is my primary indication, what does my insurance cover, what is my out-of-pocket cost, and what supply is available? A clinician familiar with both will look at your diagnoses, your BMI, your comorbidities (including type 2 diabetes, sleep apnea, cardiovascular disease, kidney disease), and the labeled indications before recommending a brand.
If you have type 2 diabetes, Mounjaro is the indicated product. If you have obesity without diabetes — or obesity with sleep apnea — Zepbound is the indicated product. If you have both diabetes and obesity, your prescriber has to choose which indication to bill under, and coverage usually drives the answer.
GLP1Zoom doesn't prescribe or sell medication — we compare and redirect to licensed providers. We aggregate pricing, coverage information, and provider options so you walk into your appointment informed. The clinical decision, dose selection, monitoring, and follow-up belong to your prescriber.
The bigger picture: why dual branding is becoming common
Tirzepatide is not the first molecule to live under two brand names. Novo Nordisk markets semaglutide as Ozempic for type 2 diabetes, Wegovy for chronic weight management, and Rybelsus as an oral form for diabetes. Liraglutide was sold as Victoza for diabetes and Saxenda for weight management. Bupropion was sold as Wellbutrin for depression and Zyban for smoking cessation decades earlier — the same playbook.
Dual branding serves several purposes: it allows manufacturers to tailor pricing to different payer environments, gives sales and marketing teams a single therapeutic focus, makes pharmacy benefit management cleaner, and helps prevent off-label prescribing from blurring data on the labeled population. It also lets one product remain in stock for its indicated population during a shortage that affects the other brand.
For patients, the takeaway is straightforward: the brand on your pen does not change the molecule inside it. What changes is who pays, how much, and how easy it is to refill. As coverage for anti-obesity medications expands and as long-term outcomes data accumulates, the practical gap between brands may shrink — but for now, the brand still drives the economics.
Quick comparison at a glance
Below is a high-level summary of how the two brands compare across the dimensions patients typically ask about. Specific coverage and pricing will depend on your individual plan, location, and the manufacturer's current terms. Always confirm details with your insurer, pharmacy, and prescriber before assuming what you will pay.
Active ingredient: tirzepatide for both — identical molecule, identical pharmacology.
FDA indication — Mounjaro: type 2 diabetes in adults.
FDA indication — Zepbound: chronic weight management in adults with obesity or overweight with a weight-related condition, and moderate-to-severe obstructive sleep apnea in adults with obesity.
Dose strengths: same for both (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) given once weekly by subcutaneous injection.
Insurance: Mounjaro typically routed through diabetes coverage; Zepbound depends on whether the plan covers anti-obesity medications (and now OSA).
Self-pay options: Zepbound has direct-to-patient vials via LillyDirect; Mounjaro generally does not have an equivalent cash-pay channel.
Side effects: the same — predominantly gastrointestinal — with the same boxed warning and contraindications.
Frequently asked questions
Is Mounjaro the same drug as Zepbound?
Yes. Mounjaro and Zepbound both contain tirzepatide, the same active ingredient made by Eli Lilly. They come in the same dose strengths and are administered the same way — a once-weekly subcutaneous injection. The two brands exist because the FDA approves drugs for specific indications: Mounjaro is approved for type 2 diabetes, and Zepbound is approved for chronic weight management and obstructive sleep apnea in adults with obesity.
Why is Zepbound sometimes cheaper than Mounjaro for cash-paying patients?
Zepbound has a direct-to-patient cash channel called LillyDirect that sells single-dose vials at reduced prices for eligible self-pay patients. Mounjaro does not have an equivalent program because it is intended to be billed through diabetes insurance coverage. As a result, cash-paying patients seeking tirzepatide for weight management often find Zepbound vials more affordable than the Mounjaro pen, though list prices for the pens are similar.
Can I take Mounjaro for weight loss?
Mounjaro is FDA-approved only for type 2 diabetes, not weight loss. While weight loss is a documented effect of tirzepatide in clinical trials, prescribing Mounjaro specifically for weight management is considered off-label. Zepbound is the FDA-approved tirzepatide brand for chronic weight management and for obstructive sleep apnea in adults with obesity. Talk to your prescriber about which brand matches your indication and what your insurance covers.
Will my insurance cover Mounjaro or Zepbound?
Coverage depends on your plan and your diagnosis. Mounjaro is more commonly covered when prescribed for type 2 diabetes, often with prior authorization. Zepbound coverage for obesity varies widely; many employer plans and Medicare Part D historically excluded anti-obesity medications, though that is changing. The recent FDA approval for sleep apnea may open additional coverage paths. Check your formulary, prior authorization criteria, and any manufacturer savings card before assuming a specific cost.
Are the side effects of Mounjaro and Zepbound the same?
Yes, because they are the same drug. The most common side effects in clinical trials were gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — particularly during dose escalation. Both products carry the same boxed warning for thyroid C-cell tumors and the same contraindications. Both also carry warnings about pancreatitis, gallbladder disease, hypoglycemia when combined with insulin or sulfonylureas, kidney injury, and severe allergic reactions. Discuss any new symptoms with your prescriber.
Can I switch from Mounjaro to Zepbound or vice versa?
Clinically, switching is straightforward because the active drug is identical at the same dose. However, the prescription must be written under the brand that matches your FDA-approved indication. A switch is usually driven by changes in insurance coverage, supply, or a new diagnosis. Only your prescriber can decide whether a switch is appropriate, document the correct indication, and ensure the dose continues without interruption. Do not switch on your own without medical guidance.
Is compounded tirzepatide the same as Mounjaro or Zepbound?
No. Compounded tirzepatide is prepared by individual compounding pharmacies and is not FDA-approved as a finished product, even when the active ingredient is the same molecule. The FDA removed tirzepatide from its official shortage list in late 2024, which significantly restricted large-scale compounding. Quality, purity, and dosing accuracy can vary by pharmacy. Anyone considering compounded tirzepatide should discuss the regulatory status, source, and risks with a licensed clinician.
We cite primary sources — FDA-approved prescribing information (DailyMed), ClinicalTrials.gov registry IDs, and peer-reviewed publications — over secondary commentary. Every medical claim is re-checked at least every 6 months. Spot something wrong? Tell us. See our full editorial policy.